An evaluation of clinical response to piperazine oestrone sulphate ('Harmogen') in menopause patients.
D000328:Adult; D000568:Amenorrhea; D001284:Atrophy / Q000188:drug therapy; D002986:Clinical Trials as Topic; D045166:Estradiol Congeners / Q000627:therapeutic use*; D004967:Estrogens / Q000172:deficiency; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D004970:Estrone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D011539:Pruritus Vulvae / Q000517:prevention & control; D013997:Time Factors; D014621:Vagina / Q000166:cytology
D045166:Estradiol Congeners; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D010879:Piperazines; D010919:Placebos; D004970:Estrone; D004997:Ethinyl Estradiol; C009927:estropipate